Pharmaceuticals

Haisen Pharm

Haisen Pharm released FY2026 Q1 earnings on April 27 (BJT), actual revenue CNY 107.19 M, actual EPS CNY 0.19

Haisen Pharm released FY2025 annual earnings on March 25, 2026 (BJT) with actual revenue of CNY 532.26 M and EPS of CNY 0.89

Haisen Pharm released FY2025 Q4 earnings on March 25 (BJT), actual revenue CNY 173.39 M, actual EPS CNY 0.3086

Haisen Pharm released FY2025 9 Months Earnings on October 21, 2025 (BJT), with actual revenue of CNY 358.87 M and EPS of CNY 0.5772

Haisen Pharm released FY2025 Q3 earnings on October 21, 2025 (BJT), with actual revenue of CNY 116.78 M and EPS of CNY 0.18

Haisen Pharm released FY2025 Semi-Annual Earnings on August 14, 2025 (BJT), Actual Revenue: CNY 242.09 M, Actual EPS: CNY 0.3972

Haisen Pharm released FY2025 Q2 earnings on August 14 (BJT), actual revenue CNY 123.61 M, actual EPS CNY 0.1972

Huasen Pharmaceutical's ESG Rating Results Announced

HSY Pharma's Director and Senior Executives ELin Reduce 479,800 Shares

Haishen Pharmaceutical's Director and Senior Manager Ailin Reduced Shares by 60,600

Haiseen Pharmaceutical Discloses R&D Progress of Pipeline Products

Director of Haisen Pharmaceutical Plans to Reduce Shares

Haisen Pharm released FY2025 Q1 earnings on April 25 (BJT), actual revenue CNY 118.48 M, actual EPS CNY 0.2

Haisen Pharm released FY2024 Q4 earnings on March 27, 2025 (BJT), actual revenue CNY 151.47 M, actual EPS CNY 0.2404

Haisen Pharm released FY2024 Annual Earnings on March 27 (BJT), actual revenue CNY 471.51 M, actual EPS CNY 0.82

Haisen Pharm released FY2024 Q3 earnings on October 17 (BJT), actual revenue CNY 109.41 M, actual EPS CNY 0.19

Haisen Pharm released FY2024 9 Months Earnings on October 17, 2024 (BJT) with actual revenue of CNY 320.04 M and EPS of CNY 0.5797

Heisen Pharmaceuticals signs investment cooperation agreement for the construction of a new plant area with Zhejiang Dongyang Economic Development Zone

Haisen Pharm released FY2024 Semi-Annual Earnings on August 27 (BJT), actual revenue CNY 210.64 M, actual EPS CNY 0.39

Haisen Pharm released FY2024 Q2 earnings on August 27 (BJT), actual revenue CNY 94.84 M, actual EPS CNY 0.1677

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

Senate Minority Leader Chuck Schumer criticized Donald Trump's recent trip to China, labeling it a 'photo op' that failed to address key issues such as fentanyl, Taiwan, U.S. manufacturing, and AI. Schumer stated that Trump returned with 'nothing to show for it' and highlighted concerns over the lack of action on fentanyl flow, protections for U.S. manufacturers, and doubts regarding U.S. commitment to Taiwan.

benzinga_article

NVIDIA

Alibaba

BABA-W

TENCENT

Tencent

NVIDIA Corporation

BABA-WR

Alibaba HK SDR 5to1

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Chuck Schumer Slams Trump China Trip As 'Photo Op' With Xi Jinping, Says Visit Delivers 'Nothing' On Fentanyl, Taiwan And AI

001367

Haisen Pharm released its Q3 2025 report, with operating revenue for the first three quarters at 359 million yuan, a year-on-year increase of 12.13%. The net profit attributable to the parent company was 88.2096 million yuan, a year-on-year increase of 1.45%. The net profit after deducting non-recurring gains and losses was 84.758 million yuan, a year-on-year decrease of 1.56%. The basic earnings per share were 0.59 yuan

Zhitong

Haisen Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 88.2096 million yuan, an increase of 1.45%

Haisen Pharm announced that in the first half of 2025, operating income was 242 million yuan, a year-on-year increase of 14.93%; net profit was 60.7942 million yuan, a year-on-year increase of 4.74%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

Haisen Pharm: Net profit of 60.7942 million yuan in the first half of 2025, a year-on-year increase of 4.74%

002275

300199

300436

002728

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit

Guilin Sanjin

HYBIO

Cosunter

TY PHAR.

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

According to the announcement from Haisen Pharm, director and general manager Ailin, who holds 3.96% of the company's shares, plans to reduce his holdings by 1.4721 million shares (accounting for 0.97% of the company's total share capital) through centralized bidding or block trading within three months after the disclosure of this announcement, specifically from June 24, 2025, to September 23, 2025

Haisen Pharm General Manager Ai Lin plans to reduce holdings of no more than 0.97% of shares

According to the announcement from Haisen Pharm, the company plans to distribute a cash dividend of RMB 1.70 (tax included) for every 10 shares to all shareholders in the 2024 fiscal year, and to increase the share capital by 4.8 shares for every 10 shares from the capital reserve. The equity distribution registration date is May 19, 2025, and the ex-dividend date is May 20, 2025

Haisen Pharm plans to distribute RMB 1.7 for every 10 shares and convert it into 4.8 shares, with the ex-dividend date on May 20, 2024

301252

301613

603535

001380

Stimulated by the news of BYD's large-scale stock transfer plan released last night, high stock transfer concept stocks were active in the morning session, with Kobalt, Alnera, Jiacheng International, Hwaway Technology, and Haisen Pharm hitting the daily limit, while Jiyang Precision and Tongxing both rose over 10%

Tongxing

Alnera

Jiacheng International

Hwaway Technology

BYD COMPANY

The concept of high stock splits was active in the morning session, with stocks like Kobalt and others hitting the daily limit

Haisen Pharm released its 2024 annual report, with operating revenue of 472 million yuan, a year-on-year increase of 18.63%; net profit attributable to the parent company was 123 million yuan, a year-on-year increase of 17.09%. The net profit excluding non-recurring gains and losses was 117 million yuan, a year-on-year increase of 15.02%. Basic earnings per share were 1.22 yuan, with a proposed cash dividend of 1.70 yuan for every 10 shares, and a bonus issue of 4.8 shares. All business segments achieved sales growth, with raw materials, intermediates, and formulations increasing by 16.74%, 35.51%, and 45.82%, respectively

Haisen Pharm released its 2024 annual performance, with a net profit attributable to the parent company of 123 million yuan, an increase of 17.09%

Haisen Pharm(001367.SZ)